To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Certara (NasdaqGS:CERT) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker2Good day, and thank you for standing by. Welcome to the Certara Q3 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you need to press Star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press Star 11 again. Please be advised ...

Third Quarter 2025 Financial Results November 6, 2025 Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the "Company," "Certara," "we," "us," and "our" refer to Certara, Inc. and its consolidated subsidiaries. Trademarks and Service Marks The Certara design logo, "Certara," and ou ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39799 Certara, Inc. (Exact name of registrant as specified in its charter) (St ...

Exhibit 99.1 Certara Reports Third Quarter 2025 Financial Results Updates Full Year 2025 Financial Guidance RADNOR, PA— November 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: "In the third quarter, we continued to make good progress towards our full-year revenue and profitability targets," said William Feehery, Chief Executive Officer. "We recently launched ...

Updates Full Year 2025 Financial GuidanceRADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Servi ...

New cloud capabilities cut time to create Tables, Figures, and Listings by 50%RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific ...

Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapiesRADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution. QSP has rapidly become a cornerstone of modern drug discovery and development with QSP-based FDA submissions having nearly d ...

Core Insights - Certara, Inc. has published over 200 papers in the past year and has 11 scientists listed among the top 2% most cited researchers globally according to the 2025 Stanford/Elsevier ranking, highlighting its significant impact in pharmaceutical research [1][2][3] Company Achievements - The company has maintained its leadership in pharmacology and pharmacokinetics, with its scientists recognized for their contributions either in the calendar year 2024 or throughout their careers [3] - Amin Rostami-Hodjegan, a key figure at Certara, received the 2025 Lewis B. Sheiner Lecturer Award for his lifetime achievements in pharmacometric research [4] Technological Innovations - The Simcyp Simulator®, co-founded by Rostami-Hodjegan, is utilized by over 11 global regulatory agencies and has supported more than 120 FDA-approved drugs, demonstrating its effectiveness in drug development [4] - The Simcyp Consortium, consisting of 35 leading biopharmaceutical companies, is recognized as a global authority on mechanistic PBPK modeling and simulation [4] Industry Trends - New methodologies like the Simcyp Simulator are crucial as the biopharma industry shifts away from animal testing, a transition supported by the FDA and NIH [5] - Certara has been at the forefront of reducing animal use in pre-clinical research for the past 25 years, aligning with industry trends towards more ethical research practices [5]